DEINOVE- Second convening to a Combined General Meeting on June 21, 2021
28 Maggio 2021 - 5:45PM
DEINOVE- Second convening to a Combined General Meeting on June 21,
2021
DEINOVE- Second convening to a Combined General
Meeting on June 21, 2021
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company, pioneer in the exploration and exploitation of
bacterial biodiversity to address the urgent, global challenge of
antibiotic resistance, informs its shareholders that the combined
Annual General Meeting (AGM) held on May 27, 2021 was unable to
deliberate, as the required quorum was not reached, and that a new
AGM will be held on June 21, 2021 at 2 pm CEST, in the premises of
Fieldfisher, 48 rue Cambon, 75001 Paris, to deliberate on the same
agenda.
DEINOVE’s combined AGM was held yesterday. The
shareholders who were present, duly represented or who had voted
remotely owned collectively 2,724,731 actions, representing 9.84 %
of the share capital.
Therefore, in the absence of the quorum required
to rule on the ordinary and extraordinary resolutions, none of the
proposed resolutions as listed in the meeting notice published in
the French official legal bulletin Bulletin des Annonces Légales
Obligatoires (BALO) no 48, dated April 21, 2021, has been put to
the vote of the shareholders.
The shareholders are hereby invited to a second
AGM held on Monday, June 21, 2021 at 2 pm CEST in the premises
of Fieldfisher, 48 rue Cambon, 75001 Paris, to deliberate on the
same agenda. A second convening notice will be published on June 2,
2021 in the BALO and in a legal newspaper.
All the documents regarding this AGM will be
available on the Company’s website as from June 2, 2021:
https://www.deinove.com/en/investor-room/documentation-center/general-shareholders-meeting-preparatory-documents
As a precaution, DEINOVE’s shareholders are
encouraged to anticipate their votes and to favor the use of postal
votes or proxy votes to take part in the AGM.
The shareholders’ vote for the first AGM remains
valid and counted for the second AGM.
The shareholders are strongly encouraged to vote
in advance via email.
Forms for postal vote or proxy
vote:
-
Available on request to the Company
(assemblee-generale@deinove.com)
-
Downloadable on the Company’s website:
https://www.deinove.com/en/investor-room/documentation-center/general-shareholders-meeting-preparatory-documents
Deadline for
considering voting
forms:
Friday, June 28, 2021 at 0:00 AM CEST.
Sending
methods:
- By post:
DEINOVE – A l’attention de Monsieur Mario ALCARAZ, 1682, rue de la
Valsière - CAP SIGMA, ZAC EUROMEDECINE II - 34790 Grabels
- By email:
assemblee-generale@deinove.com
Supporting
documents:
-
Registered shareholders: none
- Bearer
shareholders: certificate of account registration delivered by
their account-holding institution.
Our investor relations team is available for any
additional question: assemblee-generale@deinove.com
ABOUT DEINOVE
DEINOVE is a French biotechnology company
pioneering the exploration of a new domain of life, unexplored at
99.9%: the “microbial dark matter”. By revealing the metabolic
potential of rare bacteria or still classified as uncultivable, it
tackles a global health and economic challenge: antimicrobial
resistance.
The new therapies discovered and developed by
DEINOVE target superbugs (microbes that have become resistant to
one or more antimicrobials) that cause life-threatening infections
which are now spreading at high speed.
This breakthrough approach gave rise to one of
the world’s first specialized micro-biotechnology platforms and a
unique collection of nearly 10,000 rare strains and thousands of
bacterial extracts. Today, DEINOVE is conducting several
development programs, of which its first antibiotic candidate is
currently evaluated in a Phase II clinical trial in severe
Clostridioides difficile infections, one of the world’s first
emergencies. The Company has also developed new bacterial
micro-factories that address the other issue in the race against
antimicrobial resistance: the industrial production of these rare
and low concentrated compounds with often too complex chemical
structures to be generated by chemical synthesis.
Located at the heart of the Euromedecine park in
Montpellier, DEINOVE has been listed on EURONEXT
GROWTH® (ALDEI - code ISIN FR0010879056) since 2010. The
Company has over 50 employees and relies on a network of
world-class academic, technological, industrial and institutional
partners.
CONTACTS
InvestorsMario AlcarazChief Financial and Administrative Officer
+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners – Marie
PUVIEUX+33 (0)9 81 87 46 72 / +33 (0)6 10 54 36
72communication@deinove.com |
|